Lifeloc (OTC: LCTC) trims Q1 loss, hits SpinDetect milestone and adds $500K loan
Rhea-AI Filing Summary
Lifeloc Technologies reported first quarter 2026 net revenue of $2.294 million and a net loss of $152,713, or $(0.06) per diluted share. Revenue grew about 1% from the prior year period, while the loss narrowed from $292,686 as gross margin improved to 43% from 40%.
Research and development remained significant at more than 18% of revenue, largely funding the SpinDetect™ Centrifugal Drug Analyzer. The company completed disk production tooling and received first article disks, described as the last enabling step before beta testing. Cash stood at $569,330 as of March 31, 2026, with total assets of $6.74 million.
In May 2026, Lifeloc closed a $500,000 loan from its Chairman and CFO at 10.5% interest, adjustable with prime, with interest-only payments in 2026 and a five-year repayment schedule and no prepayment penalty.
Positive
- None.
Negative
- None.
Insights
Lifeloc showed modest Q1 revenue growth, improved margins, ongoing R&D, and added insider debt financing.
Lifeloc Technologies generated Q1 2026 net revenue of $2.294 million, up 1% year over year, and reduced its net loss to $152,713. Gross margin improved to 43% from 40%, helped by pricing and product mix, while operating expenses declined modestly.
R&D spending of $414,445 remained elevated at over 18% of revenue to advance the SpinDetect™ drug analyzer. The company reports completing disk production tooling and first article disks, indicating progress toward eventual beta testing, alongside substantially complete reader hardware and assays.
Liquidity is tighter with cash at $569,330 and quarterly operating cash outflow of $129,365. The subsequent $500,000 related-party loan at 10.5% interest adds leverage but extends funding capacity under terms management viewed as more favorable than commercial alternatives. Future filings may clarify commercialization timing and any further financing needs.
8-K Event Classification
Key Figures
Key Terms
gross margin financial
SpinDetect™ Centrifugal Drug Analyzer technical
subordinated debentures payable financial
deferred revenue financial
forward-looking statements regulatory
limit of detection technical
Earnings Snapshot
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): May 19, 2026 (
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) |
| (Address of Principal Executive Offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
On May 15, 2026, Lifeloc Technologies, Inc. (the “Company”) issued a press release announcing its operating results for the period ended March 31, 2026. This press release was made available on the Company’s website as of May 15, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
The information in this Form 8-K, including the exhibit attached hereto, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended, unless expressly set forth by specific reference in such filing that such information is incorporated by reference therein.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description |
| 99.1 | Press Release, dated May 15, 2026, issued by the Company |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: May 19, 2026 | LIFELOC TECHNOLOGIES, INC. | |
| By: | /s/ Vern D. Kornelsen | |
| Chief Financial Officer and Secretary | ||
Exhibit 99.1
Lifeloc Reports First Quarter 2026 Results and SpinDetect™ Development Milestone
WHEAT RIDGE, Colo., May 15, 2026 -- Lifeloc Technologies, Inc. (OTC: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the first quarter ended March 31, 2026.
First Quarter Financial Highlights
Lifeloc posted quarterly net revenue of $2.294 million resulting in a quarterly net loss of $(153) thousand, or $(0.06) per diluted share. These results compare to net revenue of $2.277 million and quarterly net loss of ($293) thousand, or ($0.11) per diluted share in the first quarter of 2025. Revenue increased modestly by $17 thousand, or 1%, versus the first quarter last year. Gross margin in the first quarter improved to 43% versus 40% last year, due primarily to increased pricing and a favorable product mix. Research and Development investment declined from last year, although it remains high at more than 18% of revenue, primarily for the SpinDetect™ Centrifugal Drug Analyzer development. The declining research and development investment and improving margins contributed to a smaller loss for the current period.
We believe our core alcohol detection product line-up is strong. The L-series LX9 and LT7 units have features and performance that drive market penetration by meeting previously unaddressable market needs, such as smart phone pairing, wider temperature use ranges and fast customization that incorporates local languages. We expect that sales of our newer L-series devices will be incremental to FC-series devices rather than displacing FC sales. The L-series devices have been certified to meet the requirements of most modern registration standards, such as SAI’s (Standards Australia International) latest AS 3547:2019 standards for Breath Alcohol Detectors. Our FC-series devices remain popular with many law enforcement and international organizations. Our Easycal® automated calibration station, the only automated calibration available for portable breath alcohol testers, builds valuable protection around our brand and has contributed to market share gains across the board, especially for our workplace Phoenix® 6.0 BT and EV 30 devices.
We believe our most significant long-term opportunity lies at the intersection of the global need for rapid, quantitative drug detection and our proven expertise in portable testing instrumentation. Our SpinDetect™ Centrifugal Drug Analyzer — sometimes referred to as "Lab on a Disk" — is designed to address this need, enabling rapid, on-site, quantitative drug testing for use at roadside, in emergency rooms, forensic labs, and workplace testing sites. We have demonstrated the platform's ability to effectively detect delta-9-THC, cocaine, fentanyl, amphetamine/methamphetamine, morphine, MDMA, and benzodiazepines from oral fluid. We have validated our test results against liquid chromatography-mass spectrometry (LC-MS) — the definitive laboratory standard — using real-world human saliva samples, confirming a limit of detection of approximately 10 ng/ml. Disk design represented the primary technical challenge throughout the project, requiring specialized outside expertise and multiple design iterations. We have now sufficiently tested the critical microfluidic and assay elements of the current disk design and completed fabrication of the production mold in this quarter, with first article moldings completed and delivered in April. These first article disks are currently being evaluated for performance and any potential necessary adjustment. Completing the disk production tooling is the last enabling step before beta testing can commence. We have developed reader hardware, firmware, drug assays, and reagent handling in parallel, and these are substantially complete.
Remaining tasks on the path to commercialization include collection device completion, full validation, manufacturing setup, and related ancillary tasks, and we do not anticipate that further technical breakthroughs will be required. Our initial product is planned to enable detection of delta-9-THC from oral fluid, followed by a multi-drug panel disk. We expect subsequent releases to expand to additional drug panels and to samples collected from blood and breath, as well as other applications, as well as selected non-drug applications such as food pathogen detection. We have managed R&D spending to align with cash generated by our core business, and we have sought financing on terms that do not overburden operations or excessively dilute shareholders.
In May 2026, Lifeloc closed on $500,000 of financing, securing a loan from our Chairman of the Board and CFO. This loan is detailed in our most recent 8-K filing, and the key terms are 10.5% interest, adjustable upward based on the prime rate, interest only payments in 2026, followed by monthly payments that will result in the loan being fully paid in 5 years, and no prepayment penalty. After exploring many financing options, these terms were more favorable than financing alternatives available from commercial sources.
“Getting disks from the production mold marks a key milestone in the development of the SpinDetect™ analyzer, allowing us to better validate and demonstrate the technology,” commented Dr. Wayne Willkomm, President and CEO. “Oral fluid drug screening will only be the first launching application of this technology platform, to be followed by blood, urine, and sweat applications where supported by market demand and customer preferences. Future plans also call for modifications that will allow us to penetrate other markets, particularly food pathogens.”
About Lifeloc Technologies
Lifeloc Technologies, Inc. (OTC: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com.
Forward Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties, including those described in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission, that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, expectations about new and existing products, our ability to fund operations and product development, market demand, acceptance of new and existing products, technologies and opportunities, development and commercialization timelines, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled “Risk Factors” in our SEC filings.
Phoenix® and Easycal® are registered trademarks of Lifeloc Technologies, Inc.
SpinDetect™ is a trademark of Lifeloc Technologies, Inc.
Amy
Evans
Lifeloc Technologies, Inc.
http://www.lifeloc.com
(303) 431-9500
LIFELOC TECHNOLOGIES, INC.
Condensed Balance Sheets (Unaudited)
| ASSETS | ||||||||
| CURRENT ASSETS: | March 31, 2026 | December 31, 2025 | ||||||
| Cash and cash equivalents | $ | 569,330 | $ | 746,001 | ||||
| Accounts receivable, net | 850,341 | 772,380 | ||||||
| Inventories, net | 2,794,329 | 2,633,614 | ||||||
| Federal and state income taxes receivable | 55,981 | 55,981 | ||||||
| Prepaid expenses and other | 99,282 | 60,825 | ||||||
| Total current assets | 4,369,263 | 4,268,801 | ||||||
| PROPERTY, PLANT AND EQUIPMENT: | ||||||||
| Land | 317,932 | 317,932 | ||||||
| Building | 1,928,795 | 1,928,795 | ||||||
| Real-time Alcohol Detection And Recognition equipment and software | 569,448 | 569,448 | ||||||
| Production equipment, software and space modifications | 1,366,539 | 1,366,539 | ||||||
| Office equipment, software and space modifications | 197,686 | 197,686 | ||||||
| Sales and marketing equipment and space modifications | 230,543 | 225,173 | ||||||
| Research and development equipment, software and space modifications | 1,232,790 | 1,213,195 | ||||||
| Research and development equipment, software and space modifications not in service | 14,411 | 19,595 | ||||||
| Less accumulated depreciation | (3,604,323 | ) | (3,538,455 | ) | ||||
| Total property and equipment, net | 2,253,821 | 2,299,908 | ||||||
| OTHER ASSETS: | ||||||||
| Patents, net | 69,134 | 71,039 | ||||||
| Deposits and other | 46,820 | 46,820 | ||||||
| Total other assets | 115,954 | 117,859 | ||||||
| Total assets | $ | 6,739,038 | $ | 6,686,568 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Accounts payable | $ | 615,378 | $ | 301,627 | ||||
| Term loan payable, current portion | 55,271 | 54,850 | ||||||
| Subordinated debentures payable, current portion | 34,522 | 33,371 | ||||||
| Customer and tenant deposits | 10,692 | 25,694 | ||||||
| Accrued expenses | 247,670 | 321,112 | ||||||
| Deferred revenue, current portion | 54,068 | 53,716 | ||||||
| Product warranty reserve | 46,500 | 46,500 | ||||||
| Total current liabilities | 1,064,101 | 836,870 | ||||||
| TERM LOAN PAYABLE, net of current portion and debt issuance costs | 1,044,449 | 1,058,426 | ||||||
| SUBORDINATED DEBENTURES PAYABLE, net of current portion and debt issuance costs | 672,274 | 681,343 | ||||||
| DEFERRED REVENUE, net of current portion | 7,149 | 6,151 | ||||||
| Total liabilities | 2,787,973 | 2,582,790 | ||||||
| COMMITMENTS AND CONTINGENCIES (Note 6) | — | |||||||
| STOCKHOLDERS’ EQUITY: | ||||||||
| Common stock, no par value; 50,000,000 shares authorized, 2,752,616 shares outstanding | 5,934,314 | 5,934,314 | ||||||
| Accumulated deficit | (1,983,249 | ) | (1,830,536 | ) | ||||
| Total stockholders’ equity | 3,951,065 | 4,103,778 | ||||||
| Total liabilities and stockholders’ equity | $ | 6,739,038 | $ | 6,686,568 | ||||
LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Profit (Loss) (Unaudited)
| Three Months Ended March 31, | ||||||||
| REVENUES: | 2026 | 2025 | ||||||
| Product sales | $ | 2,289,759 | $ | 2,263,047 | ||||
| Royalties | 4,053 | 5,671 | ||||||
| Rental income | — | 8,316 | ||||||
| Total | 2,293,812 | 2,277,034 | ||||||
| COST OF SALES | 1,306,738 | 1,368,468 | ||||||
| GROSS PROFIT | 987,074 | 908,566 | ||||||
| OPERATING EXPENSES: | ||||||||
| Research, development, and sustaining engineering | 414,445 | 469,680 | ||||||
| Sales and marketing | 313,229 | 334,556 | ||||||
| General and administrative | 387,402 | 384,878 | ||||||
| Total | 1,115,076 | 1,189,114 | ||||||
| OPERATING (LOSS) | (128,002 | ) | (280,548 | ) | ||||
| OTHER INCOME (EXPENSE): | ||||||||
| Interest income | 6,531 | 12,357 | ||||||
| Interest expense | (31,242 | ) | (24,495 | ) | ||||
| Total | (24,711 | ) | (12,138 | ) | ||||
| NET (LOSS) BEFORE PROVISION FOR TAXES | (152,713 | ) | (292,686 | ) | ||||
| BENEFIT FROM FEDERAL AND STATE INCOME TAXES | — | — | ||||||
| NET (LOSS) | $ | (152,713 | ) | $ | (292,686 | ) | ||
| NET (LOSS) PER SHARE, BASIC | $ | (0.06 | ) | $ | (0.11 | ) | ||
| NET (LOSS) PER SHARE, DILUTED | $ | (0.06 | ) | $ | (0.11 | ) | ||
| WEIGHTED AVERAGE SHARES, BASIC | 2,752,616 | 2,694,599 | ||||||
| WEIGHTED AVERAGE SHARES, DILUTED | 2,752,616 | 2,694,599 | ||||||
LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Changes in Stockholders’ Equity (Unaudited)
For The Three Months Ended March 31, 2026 and 2025
| 2026 | ||||||||||||||||
| Common Stock Shares | Common Stock Amount | Accumulated Deficit | Total | |||||||||||||
| Beginning balance | 2,752,616 | $ | 5,934,314 | $ | (1,830,536 | ) | $ | 4,103,778 | ||||||||
| Warrants issued with subordinated debenture | — | — | — | — | ||||||||||||
| Issuance of shares from option exercise | — | — | — | — | ||||||||||||
| Net (loss) | — | — | (152,713 | ) | (152,713 | ) | ||||||||||
| Ending balance | 2,752,616 | $ | 5,934,314 | $ | (1,983,249 | ) | $ | 3,951,065 | ||||||||
| 2025 | ||||||||||||||||
| Common Stock Shares | Common Stock Amount | Accumulated Deficit | Total | |||||||||||||
| Beginning balance | 2,664,116 | $ | 5,586,014 | $ | 639,863 | $ | 6,225,877 | |||||||||
| Warrants issued with subordinated debenture | — | 12,000 | — | 12,000 | ||||||||||||
| Issuance of shares from option exercise | 88,500 | 336,300 | — | 336,300 | ||||||||||||
| Net (loss) | — | — | (292,686 | ) | (292,686 | ) | ||||||||||
| Ending balance | 2,752,616 | $ | 5,934,314 | $ | 347,177 | $ | 6,281,491 | |||||||||
LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Cash Flows (Unaudited)
| Three Months Ended March 31, | ||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | 2026 | 2025 | ||||||
| Net (loss) | $ | (152,713 | ) | $ | (292,686 | ) | ||
| Adjustments to reconcile net (loss) to net cash (used in) operating activities- | ||||||||
| Depreciation and amortization | 67,773 | 102,406 | ||||||
| Amortization of debt issuance costs | 6,051 | 5,171 | ||||||
| Changes in operating assets and liabilities- | ||||||||
| Accounts receivable | (77,961 | ) | (29,156 | ) | ||||
| Inventories | (160,715 | ) | 54,848 | |||||
| Federal and state income taxes receivable | — | (150 | ) | |||||
| Prepaid expenses and other | (38,457 | ) | (329,643 | ) | ||||
| Deposits and other | — | (562 | ) | |||||
| Accounts payable | 313,751 | 342,625 | ||||||
| Customer and tenant deposits | (15,002 | ) | 80,395 | |||||
| Accrued expenses | (73,442 | ) | (49,347 | ) | ||||
| Deferred revenue | 1,350 | 15,742 | ||||||
| Net cash (used in) operating activities | (129,365 | ) | (100,357 | ) | ||||
| CASH FLOWS (USED IN) INVESTING ACTIVITIES: | ||||||||
| Purchases of sales and marketing equipment | (5,370 | ) | — | |||||
| Purchases of research and development equipment, software and space modifications | (14,411 | ) | (18,548 | ) | ||||
| Net cash (used in) investing activities | (19,781 | ) | (18,548 | ) | ||||
| CASH FLOWS (USED IN) FINANCING ACTIVITIES: | ||||||||
| Principal payments made on term loan | (14,093 | ) | (13,684 | ) | ||||
| Proceeds from issuance of subordinated debenture | — | 75,000 | ||||||
| Principal payments made on subordinated debentures | (13,432 | ) | — | |||||
| Proceeds from issuance of shares from option exercise | — | 336,300 | ||||||
| Net cash provided from (used in) financing activities | (27,525 | ) | 397,616 | |||||
| NET INCREASE (DECREASE) IN CASH | (176,671 | ) | 278,711 | |||||
| CASH, BEGINNING OF PERIOD | 746,001 | 1,243,746 | ||||||
| CASH, END OF PERIOD | $ | 569,330 | $ | 1,522,457 | ||||
| SUPPLEMENTAL INFORMATION: | ||||||||
| Cash paid for interest | $ | 25,191 | $ | 19,324 | ||||
| Cash paid for income tax | $ | — | $ | 150 | ||||
| Non-cash financing and investing activities: warrants issued with subordinated debenture | $ | — | $ | 12,000 | ||||